Alnylam Pharmaceuticals

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ALNY and other ETFs, options, and stocks.

About ALNY

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R.

CEO

Yvonne L. Greenstreet

CEOYvonne L. Greenstreet

Employees

2,500

Employees2,500

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

2002

Founded2002

Employees

2,500

Employees2,500

ALNY Key Statistics

Market cap

40.54B

Market cap40.54B

Price-Earnings ratio

69.52

Price-Earnings ratio69.52

Dividend yield

—

Dividend yield—

Average volume

1.02M

Average volume1.02M

High today

$310.08

High today$310.08

Low today

$293.85

Low today$293.85

Open price

$296.95

Open price$296.95

Volume

1.08M

Volume1.08M

52 Week high

$495.55

52 Week high$495.55

52 Week low

$283.10

52 Week low$283.10

Stock Snapshot

With a market cap of 40.54B, Alnylam Pharmaceuticals(ALNY) trades at $303.64. The stock has a price-to-earnings ratio of 69.52.

As of 2026-06-05, Alnylam Pharmaceuticals(ALNY) stock has fluctuated between $293.85 and $310.08. The current price stands at $303.64, placing the stock +3.3% above today's low and -2.1% off the high.

The Alnylam Pharmaceuticals(ALNY)'s current trading volume is 1.08M, compared to an average daily volume of 1.02M.

During the past year, Alnylam Pharmaceuticals(ALNY) stock moved between $283.10 at its lowest and $495.55 at its peak.

ALNY News

Benzinga 12h

Alnylam Eyes Faster Drug Discovery With AI Partnership Worth Up To $2 Billion

The partnership aims to enhance the discovery of RNA interference (RNAi) therapeutics by integrating Alnylam’s RNAi platform with Inceptive’s AI expertise, pote...

Simply Wall St 20h

AI Collaboration Puts Alnylam’s RNAi Pipeline Productivity In Focus

Alnylam Pharmaceuticals (NasdaqGS:ALNY) has announced a new collaboration with AI firm Inceptive Nucleics focused on accelerating RNAi drug discovery. The part...

Nasdaq 22h

Alnylam, Inceptive Ink AI Drug Development Deal Worth Up To $2 Bln

(RTTNews) - Alnylam Pharmaceuticals, Inc. (ALNY) announced partnership with Inceptive Nucleics, Inc., an artificial intelligence-driven biotechnology company, i...

Analyst ratings

71%

of 31 ratings

Buy

71%

Hold

29%

Sell

More ALNY News

TipRanks 1d

Alnylam, Inceptive form strategic AI collaboration

The company states: “Alnylam (ALNY) Pharmaceuticals and Inceptive Nucleics, Inc. announced a strategic collaboration agreement to increase the pace of therapeut...

Nasdaq 5d

Are Options Traders Betting on a Big Move in Alnylam Stock?

Investors in Alnylam Pharmaceuticals, Inc. ALNY need to pay close attention to the stock based on moves in the options market lately. That is because the July 1...

People also own

Based on the portfolios of people who own ALNY. This list is generated using Robinhood data, and it’s not a recommendation.

Eli Lilly

Vertex Pharmaceuticals

Taiwan Semiconductor Manu…

Novo Nordisk

Netflix

Meta Platforms

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.